Welcome to our dedicated page for HTBX news (Ticker: HTBX), a resource for investors and traders seeking the latest updates and insights on HTBX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HTBX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HTBX's position in the market.
Heat Biologics (NASDAQ:HTBX) announced the issuance of US Patent No. 10,758,611 for its gp96 platform combined with a T cell costimulatory agonist. This novel therapy has shown superior pre-clinical activity compared to traditional systemic approaches. The combination offers benefits like enhanced memory T cell response and reduced systemic toxicity. CEO Jeff Wolf highlighted the potential breakthrough in treating cancer and infectious diseases, including COVID-19. Current trials are underway for gp96 (HS-110) and OX40L (HS-130), with plans for more updates ahead.
Heat Biologics has published positive preclinical results for its gp96-based COVID-19 vaccine, highlighting its ability to induce systemic and tissue-specific memory CD8+ T cells. This vaccine shows promise in enhancing cellular immunity against SARS-CoV-2, potentially benefiting high-risk populations, such as the elderly and immunocompromised individuals. It demonstrates significant increases in CD8+ T-cell frequency and robust immune response against the Spike protein of the virus. The findings suggest a potential for durable protection against reinfection.
Heat Biologics (NASDAQ: HTBX) announced preclinical results for its gp96-based COVID-19 vaccine, showing a robust T cell immune response after a single dose. Developed at the University of Miami, the vaccine triggered the expansion of CD8+ and CD4+ T cells, which are essential for combating SARS-CoV-2. CEO Jeff Wolf emphasized the potential of their vaccine in enhancing efficacy when used alone or alongside existing vaccines. The company plans to publish full study details soon, while continuing to advance other product candidates in its pipeline.
Heat Biologics (NASDAQ:HTBX) announced promising preclinical data for its gp96-based COVID-19 vaccine, demonstrating robust T cell-driven immune responses against SARS-CoV-2. Conducted at the University of Miami, the study showed significant expansion of CD8+ and CD4+ T cells following a single dose, enhancing the anti-viral immune response. The CEO expressed optimism about the vaccine's unique capability to generate T cell immunity, potentially allowing it to complement existing vaccine approaches. Further details of the study are expected soon.